Safety Study of JTT-302 in Subjects With Low HDL-C Levels
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or
 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid
 parameters and CETP activity and mass.
Inclusion Criteria:

 -  Subjects must have successfully completed the 4-week treatment period of study
 AT302-U-06-003

 Exclusion Criteria:

 -  Females who are pregnant or lactating, and females of child bearing potential who are
 not using an effective method of contraception

 -  Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol

 -  Subjects who cannot follow the prescription and OTC medication restrictions defined in
 the protocol

 -  Flu-shots not permitted during the study, including the follow-up period.